Axon Enterprise (NASDAQ:AXON) Shares Up 5.9% – What’s Next?

Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report)’s stock price rose 5.9% on Thursday. The stock traded as high as $325.66 and last traded at $318.5470. 385,969 shares traded hands during trading, a decline of 65% from the average daily volume of 1,101,769 shares. The stock had previously closed at $300.69.

Analyst Ratings Changes

A number of research firms recently commented on AXON. Northcoast Research lifted their target price on Axon Enterprise from $650.00 to $680.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $540.00 price target (down from $561.00) on shares of Axon Enterprise in a research note on Friday, November 6th. The Goldman Sachs Group lowered their target price on shares of Axon Enterprise from $715.00 to $675.00 and set a “buy” rating on the stock in a research note on Monday, September 21st. Argus increased their target price on shares of Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Finally, Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “hold” rating and set a $390.00 price objective for the company. in a research note on Friday, November 6th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $612.18.

View Our Latest Research Report on Axon Enterprise

Axon Enterprise Price Performance

The company’s 50 day moving average is $398.48 and its 200 day moving average is $462.93. The company has a current ratio of 3.00, a quick ratio of 2.60 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $23.71 billion, a price-to-earnings ratio of 93.31, a price-to-earnings-growth ratio of 5.82 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its earnings results on Friday, November 6th. The biotechnology company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.89 by ($0.17). The company had revenue of $908.55 million during the quarter, compared to analysts’ expectations of $934.33 million. Axon Enterprise had a net margin of 7.56% and a return on equity of 3.87%. The company’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.17 earnings per share. Research analysts anticipate that Axon Enterprise, Inc will post 1.65 EPS for the current fiscal year.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total value of $5,089,900.00. Following the sale, the chief executive officer directly owned 3,118,012 shares in the company, valued at approximately $1,587,036,927.88. This trade represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Isaiah Fields sold 1,017 shares of Axon Enterprise stock in a transaction on Friday, September 11th. The shares were sold at an average price of $480.45, for a total value of $488,617.65. Following the sale, the insider directly owned 56,264 shares in the company, valued at $27,032,038.80. The trade was a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 27,792 shares of company stock worth $15,214,581. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds have recently made changes to their positions in AXON. Forefront Wealth Partners LLC raised its holdings in shares of Axon Enterprise by 4.6% during the 3rd quarter. Forefront Wealth Partners LLC now owns 1,362 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 60 shares in the last quarter. American Century Companies Inc. grew its holdings in Axon Enterprise by 71.2% during the third quarter. American Century Companies Inc. now owns 271,417 shares of the biotechnology company’s stock valued at $114,679,000 after purchasing an additional 112,838 shares during the last quarter. PCM Encore LLC bought a new position in shares of Axon Enterprise in the third quarter valued at approximately $201,000. Defiance ETFs LLC acquired a new position in Axon Enterprise in the 3rd quarter valued at $208,000. Finally, Kestra Advisory Services LLC raised its holdings in Axon Enterprise by 85.2% in the 3rd quarter. Kestra Advisory Services LLC now owns 7,119 shares of the biotechnology company’s stock worth $3,008,000 after acquiring an additional 3,276 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

(Get Free Report)

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals. The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Featured Articles

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.